Imaging studies in multiple sclerosis have shown that spinal cord atrophy correlates with clinical disability. The pathological substrate of atrophy has not as yet been investigated adequately. In order to determine the cause of spinal cord atrophy in multiple sclerosis, five different sections of the spinal cord were examined histopathologically in 33 controls and 55 multiple sclerosis cases. In the multiple sclerosis cases in each section the total lesion load and the cross-sectional area of the cord were measured. Multiple regression models were estimated, controlling for sex, age, duration of the disease and location of the cord sections. The multiple sclerosis cords were found to be significantly smaller than the controls. The duration of the disease played the most important role in determining cord atrophy. The degree of atrophy varied in different parts of the cord. Individual lesions played a minor role in local atrophy. Our findings suggest that axonal degeneration, possibly caused by the
PubMedID: 26280173 | A Longitudinal Study of Disability, Cognition and Gray Matter Atrophy in Early Multiple Sclerosis Patients According to Evidence of Disease Activity. | PloS one | 8/17/2015
Benign multiple sclerosis (BMS) occurs in about 15% of patients with relapsing-remitting multiple sclerosis (RRMS) that over time do not develop significant neurological disability. The molecular events associated with BMS are not clearly understood. This study sought to underlie the biological mechanisms associated with BMS. Blood samples obtained from a cohort of 31 patients with BMS and 36 patients with RRMS were applied for gene expression microarray analysis using HG-U133A-2 array (Affymetrix). Data were analyzed by Partek and pathway reconstruction was performed by Ingenuity for the most informative genes (MIGs). We identified a differing gene expression signature of 406 MIGs between BMS patients, mean±SE age 44.5±1.5 years, 24 females, 7 males, EDSS 1.9±0.2, disease duration 17.0±1.3 years, and RRMS patients, age 40.3±1.8 years, 24 females, 12 males, EDSS 3.5±0.2, disease duration 10.9±1.4 years. The signature was enriched by genes related RNA polymerase I (POL-1) transcription, general
Researchers from the University of Nottingham and Nottingham University Hospitals found a new way of using MRI scans to help detect the signs of multiple sclerosis in the brain. Multiple sclerosis can be difficult to diagnose as many do not experience symptoms for quite some time and symptoms may overlap with other conditions as well. MRI scans can be helpful in diagnosing multiple sclerosis at they can detect white matter lesions in the brain, but unfortunately these lesions do not always indicate multiple sclerosis.. The researchers found a way to use MRI scans to distinguish between lesions and other white spots in the brain which can be found in multiple sclerosis. The clinical MRI scanners can conduct a specific type of scan known as T2-weighted imaging, which can detect lesions in the brains white matter centered on a vein - a known indicator of multiple sclerosis.. Study lead Dr. Nikos Evangelou said, "We already knew that large research MRI scanners could detect the proportion of ...
Sleep disorders and epileptic seizures are of higher prevalence in those with multiple sclerosis. Multiple sclerosis is a chronic disease that affects the nervous system. Multiple studies have shown higher prevalence of other co-morbid disorders in those with multiple sclerosis, including sleep disorders and epileptic seizures.. One study conducted a large scale review of other research in regards to multiple sclerosis, sleep disorders and epileptic seizures. They evaluated 32 studies regarding seizures and 18 studies involving sleep disorders. Prevalence of seizures in multiple sclerosis patients was 2.28 percent and sleep disorders was 1.6 percent for narcolepsy, 14.5 - 57.5 percent for restless leg syndrome, 2.22 - 3.2 percent for REM behavior disorder and 7.14 - 58.1 percent for obstructive sleep apnea.. The review of the literature revealed that there are higher occurrences of sleep disorders and seizures in those with multiple sclerosis. The review acknowledged gaps in the research and ...
First multiple sclerosis (MS) therapy to achieve positive NICE recommendation in the shortest possible timeframe Mavenclad has shown sustained
1. Havrdová E. Roztroušená skleróza mozkomíšní. In: Havrdová E (ed). Neuroimunologie. 3rd ed. Praha: Maxdorf 2001: 231. 2. Benedict RH. Integrating cognitive function screening and assessment into the routine care of multiple sclerosis patients. CNS Spectr 2005; 10(5): 384-391. 3. Rao SM, Leo GJ, Bernardin L, Unverzang F. Cognitive dysfunction in multiple sclerosis. Frequency, patterns and prediction. Neurology 1991; 41(5): 685-691. 4. Jennekens-Schinkel A, Sanders EA. Decline of cognition in multiple sclerosis: dissociable deficits. J Neurol Neurosurg Psychiatry 1986; 49(12): 1354-1360. 5. Peyser JM, Edwards KR, Poser CM, Filskov SB. Cognitive function in patients with multiple sclerosis. Arch Neurol 1980; 37(9): 577-579. 6. Rao SM. Multiple sclerosis. In: Cummings JL (ed). Subcortical demention. New York: Oxford University Press 1990: 164-180. 7. Feldman RG, Albert ML, Willis AL. The "subcortical dementia" of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1974; 37(2): ...
... is a disease of the central nervous system, brain, optic nerve, and spinal cord. In multiple sclerosis, the protective covering known as myelin that protects the nerves becomes damaged. Damaged myelin and damaged nerves disrupt the smooth flow of nerve impulses within the brain and between the brain, spinal cord, and body, causing the symptoms of multiple sclerosis. The areas of inflammation or damage that occur in the central nervous system are known as lesions or plaques.. Approximately 400,000 individuals have multiple sclerosis in the United States and 2.5 million worldwide. Most people are diagnosed with multiple sclerosis between the ages of 15 and 50. Women are more likely than men to develop the relapsing form of multiple sclerosis. Caucasians have a higher incidence of multiple sclerosis than those of African heritage. African Americans may experience more problems with vision and mobility. People living further from the Equator have a higher risk of multiple ...
1. Esparza ML, Sasaki S, Kesteloot H. Nutrition, latitude, and multiple sclerosis mortality: an ecologic study. Am J Epidemiol. 1995;142:733-737. 2. Lauer K. The risk of multiple sclerosis in the U.S.A. in relation to sociogeographic features: a factor-analytic study. J Clin Epidemiol. 1994;47:43-48. 3. Alter M, Yamoor M, Harshe M. Multiple sclerosis and nutrition. Arch Neurol. 1974;31:267-272. 4. Esparza ML, Sasaki S, Kesteloot H. Nutrition, latitude, and multiple sclerosis mortality: an ecologic study. Am J Epidemiol. 1995;142:733-737. 5. Swank RL. Multiple sclerosis: twenty years on low fat diet. Arch Neurol. 1970;23:460-474. 6. Swank RL, Dugan BB. Effect of low saturated fat diet in early and late cases of multiple sclerosis. Lancet.1990;336:37-39. 7. Millar JH, Zilkha KJ, Langman MJ, et al. Double-blind trial of linoleate supplementation of the diet in multiple sclerosis. Br Med J. 1973;1:765-768. 8. Bates D, Fawcett PR, Shaw DA, et al. Polyunsaturated fatty acids in treatment of acute ...
0007]The following references identify the numbers indicated above. [0008]1. Platten, M., and L. Steinman. 2005. Multiple sclerosis: trapped in deadly glue. Nature Medicine 11:252-253. [0009]2. Oksenberg, J. R., S. E. Baranzini, L. F. Barcellos, and S. L. Hauser. 2001. Multiple sclerosis: genomic rewards. Journal of neuroimmunology 113:171-184. [0010]3. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 43:655-661. [0011]4. 1998. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352:1498-1504. [0012]5. Johnson, K. P., B. R. Brooks, J. A. Cohen, C. C. Ford, J. Goldstein, R. P. Lisak, L. W. Myers, H. S. Panitch, J. W. Rose, and R. B. Schiffer. ...
Im sure you know a lot of people with diabetes. I can bet you have relatives diagnosed with hypertension. However, the chances are that you dont know anyone with multiple sclerosis.. After all, multiple sclerosis (MS) is thought to be relatively rare in the Philippines and in other tropical countries. Literally meaning "numerous scars", it is an immunologic disorder of the central nervous system, characterized by the demyelination of axons and formation of plaques.. We cant let misconceptions about multiple sclerosis contribute to diagnostic and therapeutic difficulties! Its time to do a little myth-busting.. Myth #1: "If someone in your family has it, youll have it, too". Having a family history of multiple sclerosis does not guarantee that one will get diagnosed with it later on.. Yes, the expert consensus on multiple sclerosis is that it comes with a genetic risk. Once exposed to the environmental triggers, someone genetically susceptible to MS may develop the disease.. Take note, ...
libro multiple sclerosis : The most trusted book on multiple sclerosis, updated and revised with the latest research in combating the disease.Once known as the crippler of young adults, now more than 75 percent of MS patients will never need a wheelchair. In Multiple Sclerosis, Dr. Louis J. Rosner and Shelley Ross explain that there genuinely is new hope, more than ever before, both for controlling the disease today and curing it tomorrow. Updated with the latest research and terminology, this revised edition gets to the bottom of every treatment option from the tried-and-true to todays cutting-edge and experimental therapies. Its trusted advice covers every step of living with MS, what you need to know, and what you need to ask. Dr. Louis Rosner and Shelley Ross explain what the disease is, who gets it and why, and what people with MS can do to continue living happy and healthy lives. Whether you or your loved one has just been diagnosed with MS or has lived with it for a while, Multiple Sclerosis
All site content, except where otherwise noted, is licensed under a Creative Commons BY license. Please let us know where and how you use MSDF material ...
The following article presents the very latest information on Multiple Sclerosis. If you have a particular interest in Multiple Sclerosis, then this informative article is required reading.. What the physicians think. Doctors at Liverpool have discovered a drug that can be considered as a miracle treatment for multiple sclerosis, a debilitating and muscle-wasting disease. The scientists held their research and tests at the Walton Neurological Centre and they claim that they have just heralded a breakthrough for the eighty-five thousand multiple sclerotic people in the United Kingdom.. Those who had multiple sclerosis, otherwise known as MS, who suffered from blindness, immobility and paralysis, have described the moments when they have eventually regained their ability to see and to walk again.. What the doctors used for treating such patients were a combination of mitoxantrone, which is a drug for chemotherapy, and copaxone, which is an anti-relapse medication of multiple sclerosis.. The ...
The women who already have at least one child have a thirty-four percent less of the possibility of having a progressive state of multiple sclerosis. According to studies, those women who do not have children yet are more likely to reach a stage of MS where they would need assistance in walking with a brace or a cane.. Having a child before or after the symptoms of multiple sclerosis started to appear is of great help. On the other hand, those women who had children even after the onset of their disease?s symptoms were much better off. Either way, it seems that pregnancy helps in cases of multiple sclerosis. What the experts say. In fact, according to an expert from the Department of Neurology at the National MS Centrum which is located in Mesbroek, Belgium, named Marie D?hooghe, women who have multiple sclerosis and children tend to have a benign type of MS. This finding is in comparison to those women who have not yet given birth.. Research on multiple sclerosis indicates that eighty-five ...
Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome. - Mark S Freedman
Relief is when you and the right researcher find each other Finding the right clinical trial for Multiple sclerosis susceptibility can be challenging. However, with TrialsFinder (which uses the Reg4ALL database and privacy controls by Private Access), you can permit researchers to let you know opportunities to consider - all without revealing your identity. ...
Improved management of multiple sclerosis (MS) would result from understanding of MS pathogenesis, risk factors, immune abnormalities, and mechanism of action of MS treatments, including understanding of complications that can result from those treatments. Faculty will discuss new understanding in MS pathogenesis and how immune interventions can alter disease pathogenesis for an improved clinical outcome, and the mechanism of action of current MS therapies. This program complements C201: Multiple Sclerosis Overview: Clinical Pearls and C214: Multiple Sclerosis Overview: Clinical Advances, but covers independent topics ...
In this study, we analyzed the equilibrium between histone acetylation, mediated by HATs, and histone deacetylation, mediated by HDACs, in the NAWM of chronic MS brains. Similar to what was reported for the old rodent brain, also in the NAWM of human brains from aged individuals and chronic MS patients we detected a shift toward acetylation. This shift toward acetylation detected in a subset of female patients correlated with the consistent and reproducible increase of several histone acetyltransferase family members, including CBP, P300, MYST3, and MYST4. It is worth noting that, although we also detected increased levels of HDAC11 in this subpopulation, the increased of the acetyltransferases was much greater and likely determined the shift in favor of increased acetylation. These differences were most prominent in a subset of female MS patients and were associated with high levels of developmentally regulated genes (i.e., TCF7L2, SOX2, ID2) compared with controls. Several other genes (i.e., ...
OBJECTIVE: To examine whether past high sun exposure is associated with a reduced risk of multiple sclerosis. DESIGN: Population based case-control study. SETTING: Tasmania, latitudes 41-3 degrees S. PARTICIPANTS: 136 cases with multiple sclerosis and 272 controls randomly drawn from the community and matched on sex and year of birth. MAIN OUTCOME MEASURE: Multiple sclerosis defined by both clinical and magnetic resonance imaging criteria. RESULTS: Higher sun exposure when aged 6-15 years (average 2-3 hours or more a day in summer during weekends and holidays) was associated with a decreased risk of multiple sclerosis (adjusted odds ratio 0.31, 95% confidence interval 0.16 to 0.59). Higher exposure in winter seemed more important than higher exposure in summer. Greater actinic damage was also independently associated with a decreased risk of multiple sclerosis (0.32, 0.11 to 0.88 for grades 4-6 disease). A dose-response relation was observed between multiple sclerosis and decreasing sun exposure when
Acknowledgements. None.. Financial support and sponsorship. The research of I.K.S. is supported by the National Multiple Sclerosis Society, the United States Department of Defense, and the Guthy Jackson Charitable Foundation.. REFERENCES AND RECOMMENDED READING. Papers of particular interest, published within the annual period of review, have been highlighted as: * of special interest. ** of outstanding interest 1. Belbasis L, Bellou V, Evangelou E, et al. Environmental risk factors and multiple sclerosis: An umbrella review of systematic reviews and metaanalyses. Lancet Neurol 2015; 14:263-273.. 2. Sawcer S, Franklin RJ, Ban M. Multiple sclerosis genetics. Lancet Neurol 2014; 13:700-709.. 3. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on clinical trials of new agents in multiple sclerosis. Neurology 1996; 46:907-911. 4. Kuceyeski AF, Vargas W, Dayan M, et al. Modeling ...
TY - JOUR. T1 - Lower Extremity Motor Evoked Potentials in Multiple Sclerosis. AU - Jones, Seth M.. AU - Streletz, Leopold. AU - Raab, Vicki E.. AU - Knobler, Robert L.. AU - Lublin, Fred D.. PY - 1991. Y1 - 1991. N2 - Transcranial magnetic stimulation was performed on 25 patients with definite multiple sclerosis. Motor evoked potentials were recorded from the anterior tibial muscle. Central motor conduction time was calculated using the equation (F + M-1)/2 by stimulation of the common peroneal nerve. Motor evoked potentials were capable of detecting subclinical pyramidal tract lesions in multiple sclerosis. In patients with multiple sclerosis, the incidence of abnormality of motor and somatosensory evoked potentials was similar. Central motor conduction time was correlated with overall and pyramidal tract subscores on the Kurtzke Disability Status Scale and the Scripps Neurological Rating Scale. Central motor conduction time abnormalities correlated best with the presence of a Babinskis sign ...
The study is a 24 months randomized, double-blind, Placebo-controlled, multi-center clinical trial with an optional 12 months open label extension.. The primary objective of the study is to evaluate the effect of fetal bovine serum [FBS]-free/human serum albumin [HSA]-free formulation of Interferon [IFN] beta-1a (RNF) 44 microgram (three times weekly and once weekly) versus placebo on the time to conversion to McDonald multiple sclerosis (MS) criteria (2005) in subjects with a first clinical demyelinating event at high risk of converting to MS.. The main secondary objective of study is to evaluate the effect of RNF 44 microgram (three times weekly and once weekly) versus placebo on the Time to conversion to clinically definite MS (CDMS) in subjects with a first clinical demyelinating event at high risk of converting to MS.. At the end of 24 month double-blind core REFLEX trial, subjects who will not convert to CDMS and decide to receive open-label (OL) treatment will be enrolled into an ...
An SAE was defined as any untoward medical occurrence that at any dose: results in death; in the view of the Investigator, places the subject at immediate risk of death (a life-threatening event; however, this does not include an event that, had it occurred in a more severe form, might have caused death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; or results in a congenital anomaly/birth defect. An SAE may also have been any other medically important event that, in the opinion of the Investigator, may jeopardize the subject or may require intervention to prevent one of the other outcomes listed in the definition above. See Adverse Events section below for further details ...
2) Infection. It has been theorized that multiple sclerosis can be caused by viral or bacterial infections. Over 90% of multiple sclerosis sufferers have bands of antibodies called immunoglobulins in the brain and spine fluid. These usually indicate the presence of an infectious agent to which the immune system has responded. These findings appear to indicate that an unknown or known, but unidentified virus or bacteria may trigger the onset of the disease. The theory is supported by the ability of some viruses to cause demyelination, or damage to the protective fatty myelin layer covering the tail of nerve cells.. 3) Geographical causes. Research shows an increase in multiple sclerosis cases in people living further from the equator, although exceptions exist. Northern Europeans, for example, appear to have a higher incidence of multiple sclerosis. Moreover, the disease appears to have an earlier onset in sufferers living in countries with little sunshine and cooler climates. The main ...
Allegretta M, Nicklas JA, Sriram S, Albertini RJ (1990) T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 247:718721 10. Wucherpfennig KW, Newcombe J, Li H, Keddy C, Cuzner ML, Hafler DA (1992) yo T cell receptor in acute multiple sclerosis lesions. Proc Nat! Acad Sci USA 89:4588-4592 11. Triebel F, Hercend T (1989) Subpopulations of human peripheral yo T lymphocytes. Immunol Today 10:186-188 12. Selmaj K, Brosnan CF, Raine CS (1991) Co-localization of lymphocytes bearing yo T cell receptor and heat shock protein hsp65+ oligodendrocytes in multiple sclerosis. Recent data indicate that glutamate released by electrically active neurons was indirectly involved in this inhibitory process and prevented MHC class II induction on microglia [13]. In our laboratory, glutamate (at lower concentrations, 20 flM) was found to reduce MHC class II inducibility of microglia in cultured brain tissue [13]. However, no direct effect of glutamate on isolated microglial cells ...
Objective: To investigate accidental falls and near fall incidents in people with multiple sclerosis with respect to clinical variables and the predictive values of four tests. Design: A longitudinal, multi-centred cohort study with prospectively collected falls. Procedures: Self-reported incidents during the three months following a standardized test procedure. Subjects: Seventy-six people with multiple sclerosis and an Expanded Disability Status Scale score between 3.5 and 6.0. Main outcome measures: Berg Balance Scale, Timed Up and Go cognitive, Four Square Step Test (FSST) and 12-item Multiple Sclerosis Walking Scale. Results: Forty-eight people (63%) registered 270 falls. Most falls occurred indoors during activities of daily life. We found a correlation of r(s) = 0.57 between near falls and falls, and of r(s) = 0.82 between registered and retrospectively recalled falls. Fallers and non-fallers differed significantly regarding Expanded Disability Status Score (odds ratio (OR) 1.99, 95% ...
Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis. Kuhle, Jens; Pohl, Christoph; Mehling, Matthias; Edan, Gilles; Freedman, Mark S.; Hartung, Hans-Peter; Polman, Chris H.; Miller, David H.; Montalban, Xavier; Barkhof, Frederik; Bauer, Lars; Dahms, Susanne; Lindberg, Raija; Kappos, Ludwig; Sandbrink, Rupert // New England Journal of Medicine;1/25/2007, Vol. 356 Issue 4, p371 Background: Patients with a single episode of neurologic dysfunction and brain magnetic resonance imaging (MRI) scans suggestive of multiple sclerosis are at high risk for clinically definite multiple sclerosis, but the outcome for individual patients is unpredictable. An increased risk of... ...
Treatment of Multiple sclerosis (MS) is a chronic, potentially debilitating disease that affects your central nervous system, which is made up of your brain and spinal cord. Multiple sclerosis is widely believed to be an autoimmune disease, a condition in which your immune system attacks components of your body as if theyre foreign, In multiple sclerosis, the body mistakenly directs antibodies and white blood cells against proteins in the myelin sheath, a fatty substance that insulates nerve fibers in your brain and spinal cord. This results in inflammation and injury to the sheath and ultimately to the nerves that it surrounds. The result may be multiple areas of scarring (sclerosis). Eventually, this damage can slow or block the nerve signals that control muscle coordination, strength, sensation and vision, Multiple sclerosis affects an estimated 300,000 people in the United States and probably more than 1 million people around the world - including twice as many women as men. Most people experience
According to the results of a new clinical trial, stem cell transplants are likely to induce remission of multiple sclerosis in the long run. The trial indicates that high-dose immunosuppressive therapy and transplantation of an individuals own stem cells may stimulate sustained reduction of relapsing-remitting multiple sclerosis. After five years of receiving high-dose immunosupprresive therapy treatment and autologous hematopoietic cell transplant, 69 percent of the participants did not experience continued disability. Additionally, they did not suffer from progression of MS symptoms or a relapse. Noteworthy, after obtaining HDIT/HCT, participants did not take any medication. Some studies have noted that the success rates of the present MS drugs are lower.. The National Institute of Allergy and Infectious Diseases (NIAID) were the sponsors of the trial dubbed HALT-MS. Immune Tolerance Network, which is funded by NIAID, conducted the research. The researchers published both the initial ...
The present findings suggest that some patients with multiple sclerosis have impaired olfaction-that is, about 25% on the basis of OEP and 15% on the basis of UPSIT. Our value for identification tests is slightly lower than the 23% incidence found by Doty3but much less than the 35% described by Wender and Szmeja10 and 45% documented by Pinching.9This variation may well relate to patient selection in a hospital environment. As stated, many of our patients had received a course of steroids which could have improved their olfactory tests either at the level of the nose or central olfactory pathways. It is likely that impaired smell function may occur more often during relapse as reduced olfactory ability is sometimes noted by patients during their attacks and may improve with remission or administration of steroids. As shown in figure 2, UPSIT scores for multiple sclerosis are generally low and fall off with age as do those of the controls. Although the patients with multiple sclerosis are clearly ...
Multiple Sclerosis is a type of demyelinating disease, a disease in which the nervous system is damaged by the deterioration of the outer layer of the neurons, called myelin. This phenomenon affects the transmission of the nerve impulses between neurons, which results in a variety of symptoms of multiple sclerosis, which may impair the sufferer to a certain degree. These symptoms may vary from physical, psychiatric and even mental issues. Specific symptoms of multiple sclerosis include double vision, weak muscles, and blindness in one or both eyes, difficulties with coordination or difficulties with sensations. Patients with multiple sclerosis usually experience one or more symptoms, in some cases these episodes being isolated. Between these episodes, the symptoms usually disappear completely. Nevertheless, the condition continues to develop, leaving permanent neurological damage, as the nerves continue to deteriorate. Up until the present time, the exact cause of multiple sclerosis remains ...
TY - JOUR. T1 - Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. AU - Lock, Christopher. AU - Hermans, Guy. AU - Pedotti, Rosetta. AU - Brendolan, Andrea. AU - Schadt, Eric. AU - Garren, Hideki. AU - Langer-Gould, Annette. AU - Strober, Samuel. AU - Cannella, Barbara. AU - Allard, John. AU - Klonowski, Paul. AU - Austin, Angela. AU - Lad, Nagin. AU - Kaminski, Naftali. AU - Galli, Stephen J.. AU - Kaminski, Naftali. AU - Raine, Cedric S.. AU - Heller, Renu. AU - Steinman, Lawrence. PY - 2002/1/1. Y1 - 2002/1/1. N2 - Microarray analysis of multiple sclerosis (MS) lesions obtained at autopsy revealed increased transcripts of genes encoding inflammatory cytokines, particularly interleukin-6 and - 17, interferon-γ and associated downstream pathways. Comparison of two poles of MS pathologyacute lesions with inflammation versus silent lesions without inflammation-revealed differentially transcribed genes. Some products of these ...
Objective: We are evaluating the therapeutic roles of high-dose immunosuppressive therapy (HDIT) rescued with autologous stem cell transplantation (SCT) in the management of patients with severe, nonresponsive multiple sclerosis (MS). Our hypothesis was that by ablating the immunoactive cells in a patient with MS and replacing them with nonconditional naïve cells, the disease process could be stopped. Design/Methods: We enrolled 26 patients with severe MS, including primary progressive MS (n = 7), secondary progressive MS (n = 18) and relapsing remitting MS (n = 1). Their median age was 41 years (range, 27-60). The median expanded disability status scale (EDSS) at HDIT was 7.0 (5.0-8.0). Eligibility requirements included an EDSS from 5.0 to 8.0 and deterioration of 1 or more points over the previous year. Twent-one patients had previous therapy with interferon-beta fail, and 15 had multiple therapies including Copaxone, prednisone, and methotrexate fail. The median follow-up was 12 months ...
We performed Affymetrix gene arrays (HU133, ~38,500 genes) using RNA from the in vitro activated PBMCs from patients with clinically isolated syndrome suggestive of multiple sclerosis (CIS) (n=15) and matched healthy controls (HC) (n=8). Results were confirmed and further supported by RT-PCR and RayBio Cytokine Arrays. Affymetrix data revealed that IFNB-1a induced significant (p,0.05) up-regulation of 711, and down-regulation of 587 genes in CIS patients, and 446 and 543 in HC, respectively. CXCL11 and CXCL10, the ligands of CXCR3 were significantly increased in CIS patients and HC, whereas proinflammatory chemokines CXCL2, CXCL3 and CXCL5 were decreased in CIS patients. CCL18 and CCL19 were increased in CIS, while CCL22 and CCL17 were decreased in CIS and HC. Those chemokine gene changes reflect the complex effects of IFNB-1a that likely affect differentiation/ maturation and chemotaxis of DCs and other cells bridging the innate and adaptive immune response. The anti-inflammatory cytokine IL-10 ...
Multiple sclerosis is an inflammatory neurological disease that can generate a wide range of physical and psychological symptoms. Multiple sclerosis involves the deterioration of myelin, a substance that surrounds the bodys nervous cells. Myelin has a very important role in the transmission of nervous impulses, and if this substance is affected, the entire activity of the nervous system is seriously compromised. Although the actual causes of multiple sclerosis remain unknown, there are several hypotheses that present genetic abnormalities as the main factors responsible for causing the disease. Medical scientists believe that multiple sclerosis occurs on the background of inherited genetic predispositions, and environmental factors are suspected to be triggers of the disease. Some hypotheses also introduce viral infections in this scenario, although infections with viruses dont seem to contribute to the development of the disease. Multiple sclerosis can affect the body on different levels. The ...
Multiple sclerosis. Multiple sclerosis help. Massage for multiple sclerosis. MS, MS symptoms, MS help through massage. The Haven Healing Centre. Complementary therapy in Bristol, Bath and North Somerset. Philip Chave, healer and therapist
Multiple sclerosis is a disease of the brain and spinal cord. An abnormality in the vein that drains blood from the brain and spinal cord may be associated with MS; treating this problem might hold promise as a treatment for MS.
Find and save ideas about Multiple sclerosis tattoo on Pinterest. | See more ideas about Multiple sclerosis awareness, Multiple sclerosis and Ms.
Multiple Sclerosis Treatment: Diagnosis Multiple sclerosis With a Simple Eye Scan,Multiple Sclerosis, Multiple Sclerosis Treatment, MS symptoms, natural treatment, diet, cure
Press Release issued Mar 19, 2014: According to this Natural Multiple Sclerosis Treatment System Review, Dr. Gary M. Levin writes a natural health book that provides people with a lot of proper diet plans for instant multiple sclerosis relief. Multiple sclerosis is a life-altering disease to those who have it, and to their families. It impairs a persons ability to function productively, and causes depression most of the time. To help remedy this problem, Dr. Gary M. Levin, a surgeon who has been treating the disease for years, came up with the eBook Natural Multiple Sclerosis Treatment System. This eBook focuses on alternative treatment for multiple sclerosis, which can be done at home. It works on treating the disease permanently, unlike traditional medicine that only alleviates the symptoms.
A key factor in a well Multiple Sclerosis diet is to eliminate all gluten. In general, you should avoid eating anything with flour, but you can check package ingredients if you are unsure of their content. There is no diet that will treat or cure multiple sclerosis, however there may be some connections between Multiple Sclerosis and diet. Many diets besides the Multiple Sclerosis diet do not allow gluten, so this is now easily found on many packages. Avoiding wheat, barley, oats, or rye is another way to cut gluten. People who eat too much saturated fat, processed lunch meats and sausages or have low levels of vitamin B12 or vitamin D may be at a higher risk for Multiple Sclerosis ...
Natural remedies for multiple sclerosis. Certain oils and foods may help the symptoms of multiple sclerosis. Omega-3 fatty acids in fish help multiple sclerosis.Does magnet therapy help multiple sclerosis? Does ginkgo reduce multiple sclerosis symptoms?
Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatment Leo H Visser,1,2 Marco A Heerings,3 Peter J Jongen,4,5 Karin van der Hiele1,3,6 1Department of Neurology, Elisabeth-TweeSteden Hospital, Tilburg, 2Ethics of Care, University of Humanistic Studies, Utrecht, 3National Multiple Sclerosis Foundation, Rotterdam, 4Department of Community and Occupational Medicine, University Medical Center Groningen, University of Groningen, Groningen, 5MS4 Research Institute, Nijmegen, 6Section Health, Medical and Neuropsychology, Department of Psychology, Leiden University, Leiden, the Netherlands Background: The adherence to treatment with injectable disease-modifying drugs (DMDs) in multiple sclerosis (MS) may benefit from adequate information provision and management of expectations. The communication between patients and physicians is very important in this respect. The current study investigated the perspectives
This Is MS Multiple Sclerosis Community: Knowledge Support : Welcome to the worlds leading forum on Multiple Sclerosis research, support, and knowledge. For over 10 years, This is MS has provided an unbiased community dedicated to Multiple Sclerosis patients, caregivers, ...
EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2023. Summary. Multiple sclerosis (MS) is an inflammatory disease in which the myelin sheaths around the axons of the brain and spinal cord are damaged, leading to demyelination and a wide range of signs and symptoms. MS affects 2.5 million people worldwide each year and is the most debilitating neurological disease in young adults.. GlobalData epidemiologists expect that the number of prevalent and incident cases of MS will increase during the forecast period (2013-2023) in the 10MM. In 2013, GlobalData epidemiologists forecast that there were a total of 904,908 prevalent cases of MS in the 10MM, and by 2023 GlobalData epidemiologists forecast that the number of prevalent cases will grow to 940,413 prevalent cases. During the forecast period, India will have the highest annual growth rate (AGR) at 1.99%, Spain will have the second highest (AGR: 1.05%), and China will have the third highest (AGR: 0.93%).. Visit Complete Report Here: ...
Dietitians and Multiple Sclerosis Ryan Herndon Kaplan University Professor Seeman June 26, 2012 Multiple Sclerosis (M.S.) is an autoimmune disease that
Background Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. It usually strikes during young adulthood, and 2.5 million individuals are estimated to have the disease worldwide. The causes of MS are not known, but several factors have been shown to be associated with the risk of the disease, including certain genes, vitamin D, smoking and Epstein- Barr virus infection. Little is known about how/if these factors interact.. Methods Study I: The risk of MS by month of birth was investigated using MS cases from the Swedish MS registry and using general population controls. Studies II-V: We identified MS cases who had donated blood prior to disease onset, and MS cases whose mothers had donated blood during pregnancy, by cross-linking a database of MS cases, and a database of mothers of MS cases, to two local biobank cohorts. One of them consisted of blood samples collected during early pregnancy, and one with samples collected during health controls. Levels of ...
A recent genome-wide association study (GWAS) conducted by the International Multiple Sclerosis Genetics Consortium (IMSGC) identified a number of putative MS susceptibility genes. Here we have performed a replication study in 1134 Australian MS cases and 1265 controls for 17 risk-associated single nucleotide polymorphisms (SNPs) reported by the IMSGC. Of 16 SNPs that passed quality control filters, four, each corresponding to a different non-human leukocyte antigen (HLA) gene, were associated with disease susceptibility: KIAA0350 (rs6498169) P=0.001, IL2RA (rs2104286) P=0.033, RPL5 (rs6604026) P=0.041 and CD58 (rs12044852) P=0.042. There was no association (P=0.58) between rs6897932 in the IL7R gene and the risk of MS. No interactions were detected between the replicated IMSGC SNPs and HLA-DRB1*15, gender, disease course, disease progression or age-at-onset. We used a novel Bayesian approach to estimate the extent to which our data increased or decreased evidence for association with the six ...
Multiple sclerosis is a neurological disease caused by discrete plaques of demyelination at sites throughout the central nervous system caused by a T-Cell mediated immune response with an unknown trigger. It has a lifetime risk of 1:1000 in the UK, and is twice as prevalent in females with the typical onset being between 20 and 40 years of age, namely the childbearing ages.. There are many disease-modifying therapies used to treat Multiple Sclerosis. However, immunomodulatory and immunosuppressive drugs used at any stage of pregnancy may affect fetus formation and/or development.. Interferons are a group of naturally occurring macromolecules with antiviral, antiproliferative and immunomodulatory properties, and interferon beta is currently the most widely used therapy for multiple sclerosis. However, limited data in primates suggests that interferon beta may be abortifacient. Due to this and due to lack of experience with drug safety, it is usually suggested that either treatment is suspended ...